The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -15,850,564 |
| Stock-based compensation | 187,728 |
| Depreciation | 3,918 |
| Common stock issued for license agreement | 0 |
| Loss (gain) on disposal of fixed assets | -2,559 |
| Prepaid expenses and other current assets | -302,799 |
| Accounts payable and accrued expenses | 1,542,453 |
| Net cash used in operating activities | -13,811,107 |
| Purchase of property and equipment | 18,175 |
| Net cash used in investing activities | -18,175 |
| Payments of deferred offering costs | 64,082 |
| Payments on notes payable | 297,553 |
| Stock repurchased during stock split rounding | 2,043 |
| Proceeds from subscription receivable | 882,539 |
| Proceeds from exercise of warrants | 3,627 |
| Proceeds from sale of common stock | 14,046,430 |
| Net cash provided by financing activities | 14,568,918 |
| Net change in cash and cash equivalents | 739,636 |
| Cash and cash equivalents, at beginning of period | 6,461,378 |
| Cash and cash equivalents, at end of period | 7,201,014 |
CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc. (CNSP)